Thank you farrell for your science and fact based
Post# of 72446
(Total Views: 681)
Posted On: 02/15/2021 2:28:22 AM
Thank you farrell for your science and fact based response that clearly demonstrates the clear advantages that Brilacidin has over Remdesivir. We can look forward to see this further proven in the current Brilacidin CV19 trial compared to the low bar that Remdesivir has set as the standard antiviral treatment for CV19. What is amazing is that Remdesivir shortcomings were well known in the scientific community at least as far back as when your attached article referencing the AAPS Journal dated 5/26/20.
Gilead recently stated Remdesivir revenue was $1.9B last QUARTER. What will an antiviral that actually kills the virus be worth in revenue? If you do some simple napkin math on a company with a ridiculously low expense rate and realize that most revenue will flow directly into earnings, the numbers are staggering. Throw in an Up List once revenue flow increases SP. Now throw in an eventual epic naked short squeeze and IPIX will be a completely different company in a very short period of time and it’s SP will start to reflect its true value.
Some of the comments from farrell’s posted attachment article are below.
===========================================================
“Although remdesivir is still a promising treatment for COVID-19 patients, the current clinical studies with IV administration alone are unlikely to achieve excellent clinical efficacy. Based on our analysis, even if remdesivir demonstrates benefits in the randomized controlled trials, its efficacy will be limited.”
“AT PRESENTLY ADOPTED IV DOSES, THE CONCENTRATIONS OF REMDESIVIR AND ITS ACTIVE METABOLITE ARE UNLIKELY TO BE ADEQUATE IN THE LUNG TO KILL THE SARS-CoV-2 VIRUS”
“These pharmacokinetic comparisons suggest that the exposure of remdesivir and its active metabolite in human plasma, PBMCs, and the lung after IV infusion in human (75 mg over 30 min) would be lower than or at most similar to that in monkeys (IV 10 mg/kg). Therefore, remdesivir is unlikely to be detectable in the human lung tissues.”
Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit | SpringerLink
Gilead recently stated Remdesivir revenue was $1.9B last QUARTER. What will an antiviral that actually kills the virus be worth in revenue? If you do some simple napkin math on a company with a ridiculously low expense rate and realize that most revenue will flow directly into earnings, the numbers are staggering. Throw in an Up List once revenue flow increases SP. Now throw in an eventual epic naked short squeeze and IPIX will be a completely different company in a very short period of time and it’s SP will start to reflect its true value.
Some of the comments from farrell’s posted attachment article are below.
===========================================================
“Although remdesivir is still a promising treatment for COVID-19 patients, the current clinical studies with IV administration alone are unlikely to achieve excellent clinical efficacy. Based on our analysis, even if remdesivir demonstrates benefits in the randomized controlled trials, its efficacy will be limited.”
“AT PRESENTLY ADOPTED IV DOSES, THE CONCENTRATIONS OF REMDESIVIR AND ITS ACTIVE METABOLITE ARE UNLIKELY TO BE ADEQUATE IN THE LUNG TO KILL THE SARS-CoV-2 VIRUS”
“These pharmacokinetic comparisons suggest that the exposure of remdesivir and its active metabolite in human plasma, PBMCs, and the lung after IV infusion in human (75 mg over 30 min) would be lower than or at most similar to that in monkeys (IV 10 mg/kg). Therefore, remdesivir is unlikely to be detectable in the human lung tissues.”
Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit | SpringerLink
(16)
(0)